JAK/STAT signaling is particularly important in the anti-tumor activity of PPARγ agonists because the inhibition of JAK2 (upstream regulator of STAT3) has been shown to have a role in slowing the disease progression of GBM in vivo and in vitro models (30), and troglitazone has been described as an antagonist for STAT3 signaling (31). Here, PPARG is linked to neoplasm.